Why China’s 4 + 7 policy is good news for innovative drug developers

China’s new policy on generic drugs is likely to have knock-on benefits for drug developers aiming to bring innovative compounds to the China market.

For multinationals, it will come after some pain, as they’ll see revenues drop from a scheme designed to drop generic prices -- including off-patent originator products -- by around 50%. ...